Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A
Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.
Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME
Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.
Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Pathways to the elimination of hepatitis C: prioritising access for all.
Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME
Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study.
Goutzamanis S, Doyle JS, Thompson A, Dietze P, Hellard M, Higgs P, TAP study group